BRPI0710054B8 - métodos para identificar um ou uma pluralidade de metabólitos celulares, para triar um composto de teste, e, para testar um composto de teste - Google Patents

métodos para identificar um ou uma pluralidade de metabólitos celulares, para triar um composto de teste, e, para testar um composto de teste

Info

Publication number
BRPI0710054B8
BRPI0710054B8 BRPI0710054A BRPI0710054A BRPI0710054B8 BR PI0710054 B8 BRPI0710054 B8 BR PI0710054B8 BR PI0710054 A BRPI0710054 A BR PI0710054A BR PI0710054 A BRPI0710054 A BR PI0710054A BR PI0710054 B8 BRPI0710054 B8 BR PI0710054B8
Authority
BR
Brazil
Prior art keywords
test compound
methods
identifying
testing
screening
Prior art date
Application number
BRPI0710054A
Other languages
English (en)
Inventor
G Cezar Gabriela
Original Assignee
Wisconsin Alumni Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wisconsin Alumni Res Found filed Critical Wisconsin Alumni Res Found
Publication of BRPI0710054A2 publication Critical patent/BRPI0710054A2/pt
Publication of BRPI0710054B1 publication Critical patent/BRPI0710054B1/pt
Publication of BRPI0710054B8 publication Critical patent/BRPI0710054B8/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5038—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving detection of metabolites per se
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5073—Stem cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Physiology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Other Investigation Or Analysis Of Materials By Electrical Means (AREA)

Abstract

métodos para identificar um ou uma pluralidade de metabólitos celulares, para triar um composto de teste e para testar um composto de teste, e, perfil de biomarcador para identificar um composto de teste como um composto tóxico. a invenção provê perfis de biomarcador de metabólitos celulares e métodos para triar compostos químicos incluindo agentes farmacêuticos, compostos de fármacos de ponta e candidatos e outros produtos químicos usando células-tronco embriônicas humanas (hesc) ou células específicas de linhagem produzidas a partir das mesmas. os métodos da invenção são utilizáveis para testar a toxicidade, particularmente toxicidade desenvolvimental, e detectar os efeitos teratogênicos destes compostos químicos.
BRPI0710054A 2006-04-10 2007-04-10 métodos para identificar um ou uma pluralidade de metabólitos celulares, para triar um composto de teste, e, para testar um composto de teste BRPI0710054B8 (pt)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US79064706P 2006-04-10 2006-04-10
US60/790,647 2006-04-10
US60/790647 2006-04-11
US82216306P 2006-08-11 2006-08-11
US60/822163 2006-08-11
US60/822,163 2006-08-11
PCT/US2007/008923 WO2007120699A2 (en) 2006-04-10 2007-04-10 Reagents and methods for using human embryonic stem cells to evaluate toxicity of pharmaceutical compounds & other chemicals

Publications (3)

Publication Number Publication Date
BRPI0710054A2 BRPI0710054A2 (pt) 2011-08-02
BRPI0710054B1 BRPI0710054B1 (pt) 2020-11-17
BRPI0710054B8 true BRPI0710054B8 (pt) 2021-07-27

Family

ID=38515874

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0710054A BRPI0710054B8 (pt) 2006-04-10 2007-04-10 métodos para identificar um ou uma pluralidade de metabólitos celulares, para triar um composto de teste, e, para testar um composto de teste

Country Status (11)

Country Link
US (2) US8703483B2 (pt)
EP (1) EP2013619B1 (pt)
JP (2) JP5421767B2 (pt)
BR (1) BRPI0710054B8 (pt)
CA (1) CA2648218C (pt)
DK (1) DK2013619T3 (pt)
GB (1) GB2451042A (pt)
HU (1) HUE036378T2 (pt)
MX (1) MX2008013002A (pt)
SE (2) SE1050445A1 (pt)
WO (1) WO2007120699A2 (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8153359B2 (en) 2006-10-02 2012-04-10 Cellartis Ab Toxicity assay based on human blastocyst-derived stem cells and progenitor cells
US20080187952A1 (en) * 2007-02-05 2008-08-07 Wisconsin Alumni Research Foundation Biomarkers of Ionizing Radiation Response
US7964843B2 (en) 2008-07-18 2011-06-21 The George Washington University Three-dimensional molecular imaging by infrared laser ablation electrospray ionization mass spectrometry
US20100285446A1 (en) * 2007-07-20 2010-11-11 Akos Vertes Methods for Detecting Metabolic States by Laser Ablation Electrospray Ionization Mass Spectrometry
US8067730B2 (en) 2007-07-20 2011-11-29 The George Washington University Laser ablation electrospray ionization (LAESI) for atmospheric pressure, In vivo, and imaging mass spectrometry
US8901487B2 (en) * 2007-07-20 2014-12-02 George Washington University Subcellular analysis by laser ablation electrospray ionization mass spectrometry
WO2010030293A1 (en) * 2008-09-15 2010-03-18 Gentron, Inc. Methods, systems, and compositions for cancer diagnosis
EP2406369A4 (en) * 2009-03-10 2015-12-16 Bayer Healthcare Llc METHOD FOR MONITORING CELL CULTURES
GB0911060D0 (en) 2009-06-26 2009-08-12 Ge Healthcare Uk Ltd Methods for predicting the toxicity of a chemical
CA2776383C (en) * 2009-10-06 2019-04-30 Wisconsin Alumni Research Foundation Metabolic biomarkers of drug-induced cardiotoxicity
AU2010309988A1 (en) * 2009-10-21 2012-06-14 Basf Plant Science Company Gmbh Method for generating biomarker reference patterns
US8703424B2 (en) 2010-03-22 2014-04-22 Stemina Biomarker Discovery, Inc. Predicting human developmental toxicity of pharmaceuticals using human stem-like cells and metabolomics
AU2011248464B2 (en) * 2010-04-29 2016-08-11 Stemina Biomarker Discovery, Inc. Metabolic biomarkers of autism
US8945847B2 (en) 2010-05-24 2015-02-03 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Methods and kits for ascertaining biosafety of an agent
WO2012068170A2 (en) 2010-11-15 2012-05-24 Jau-Nan Lee Generation of neural stem cells from human trophoblast stem cells
JP2014524121A (ja) 2011-07-14 2014-09-18 ザ・ジョージ・ワシントン・ユニバーシティ レーザアブレーション・エレクトロスプレイイオン化質量分析用のプルームコリメーション
US9164106B2 (en) * 2012-03-15 2015-10-20 Greenwood Genetic Center, Inc. Determination of decreased metabolism of tryptophan in diagnosis of autism spectrum disorders
MX362991B (es) * 2012-11-02 2019-03-01 Stemina Biomarker Discovery Inc Prediccion de la toxicidad de productos farmaceuticos en el desarrollo humano utilizando celulas similares a celulas madre humanas y relaciones metabolomicas.
WO2014085493A1 (en) 2012-11-30 2014-06-05 Jau-Nan Lee Methods of differentiating stem cells by modulating mir-124
WO2015003178A1 (en) * 2013-07-03 2015-01-08 Coyne Scientific, Llc Methods for predicting responses to chemical or biologic substances
US9808490B2 (en) 2014-11-26 2017-11-07 Accelerated Biosciences Corp. Induced hepatocytes and uses thereof
GB201519186D0 (en) * 2015-10-30 2015-12-16 Electrophoretics Ltd Isotopic methods for measurement of tryptophan and metabolites thereof
WO2018157004A1 (en) * 2017-02-24 2018-08-30 Coyne Scientific, Llc Methods for determining the incidence and/or intensity of effects of a chemical or biological agent on members of a target population using stem cells
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
KR102083408B1 (ko) * 2017-04-28 2020-03-02 가천대학교 산학협력단 줄기세포 기반의 독성 물질 스크리닝 방법
WO2020232436A1 (en) 2019-05-16 2020-11-19 Brown University A human in vitro cardiotoxicity model
JP7732999B2 (ja) 2020-04-03 2025-09-02 バーテックス ファーマシューティカルズ インコーポレイテッド アルファ１－アンチトリプシンのモジュレーター
CN115697969A (zh) * 2020-04-03 2023-02-03 弗特克斯药品有限公司 作为用于治疗α-1抗胰蛋白酶缺乏症(AATD)的α-1抗胰蛋白酶调节剂的7-或8-羟基-异喹啉和7-或8-羟基-喹啉衍生物
US12504423B2 (en) 2020-10-16 2025-12-23 Brown University Human in vitro cardiotoxicity model
US12076437B2 (en) 2021-07-12 2024-09-03 Brown University Proangiogenic protein cocktails delivered in custom biomaterials to revascularize ischemic tissue
KR20250002306A (ko) 2022-03-30 2025-01-07 인피니트 디.오.오. 독성 발현 및/또는 질병의 유발 및 억제를 평가하기 위한 에이전트의 예측 테스트 방법
CN121136913B (zh) * 2025-11-17 2026-04-03 杭州艾名医学科技有限公司 一种肠类器官模型体外评价药物肠毒性的方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5843780A (en) * 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
JPH11225795A (ja) 1998-02-13 1999-08-24 Oriental Yeast Co Ltd 細胞障害マーカー
DE69903800T2 (de) * 1998-03-18 2003-10-02 Massachusetts Institute Of Technology, Cambridge Vaskularisierte perfundierte anordnungen für mikrogewebe und mikroorgane
EP1287157A1 (en) * 2000-06-02 2003-03-05 Large Scale Proteomics Corporation Protein markers for pharmaceuticals and related toxicity
US6680203B2 (en) * 2000-07-10 2004-01-20 Esperion Therapeutics, Inc. Fourier transform mass spectrometry of complex biological samples
EP1176189A1 (en) * 2000-07-21 2002-01-30 Fornix Biosciences N.V. Stem cell-like cells
WO2002066635A1 (en) * 2001-02-23 2002-08-29 Gencom Corporation Transgenic animal having drug metabolism enzyme gene and utilization thereof
WO2003005628A2 (en) 2001-07-06 2003-01-16 Lipomics Technologies, Inc. Generating, viewing, interpreting, and utilizing a quantitative database of metabolites
MXPA04001725A (es) * 2001-08-24 2005-04-11 Advanced Cell Tech Inc ANáLISIS DE SELECCION PARA IDENTIFICAR AGENTES INDUCTORES DE DIFERENCIACION Y PRODUCCION DE CELULAS DIFERENCIADAS PARA TERAPIA CELULAR.
MXPA04005010A (es) * 2001-11-26 2005-04-08 Advanced Cell Tech Inc METODO PARA HACER Y USAR NUCLEOS CELULARES SOMáTICOS METODOS PARA HACER Y USAR NUCLEOS CELULARES SOMáTICOS HUMANOS REPROGRAMADOS Y CELULAS DEL TALLO HUMANAS AUTOLOGAS E ISOGENICAS.
US6982152B2 (en) * 2002-04-17 2006-01-03 Promega Corporation Cytotoxicity assay
US20040121305A1 (en) * 2002-12-18 2004-06-24 Wiegand Roger Charles Generation of efficacy, toxicity and disease signatures and methods of use thereof
WO2004065616A2 (en) 2003-01-16 2004-08-05 The General Hospital Corporation Use of three-dimensional microfabricated tissue engineered systems for pharmacologic applications
JP2005022096A (ja) 2003-06-30 2005-01-27 Three M Innovative Properties Co 遮光性装飾シート
DK1644485T3 (da) * 2003-07-08 2011-08-15 Axiogenesis Ag Udskilte proteiner som markører for celledifferentiering
CA2558946C (en) * 2003-07-08 2013-05-21 Axiogenesis Ag Novel method for the preparation of embryoid bodies (ebs) and uses thereof
GB2441530B (en) 2004-02-12 2009-09-23 Univ Newcastle Stem Cells
EP1740945B1 (en) 2004-04-07 2018-09-19 Ncardia AG Non-invasive, in vitro functional tissue assay systems

Also Published As

Publication number Publication date
CA2648218C (en) 2015-06-02
MX2008013002A (es) 2008-10-17
GB0820454D0 (en) 2008-12-17
DK2013619T3 (en) 2017-12-04
US20070248947A1 (en) 2007-10-25
GB2451042A (en) 2009-01-14
JP5421767B2 (ja) 2014-02-19
CA2648218A1 (en) 2007-10-25
JP2013078342A (ja) 2013-05-02
US8703483B2 (en) 2014-04-22
BRPI0710054B1 (pt) 2020-11-17
US20140255969A1 (en) 2014-09-11
WO2007120699A2 (en) 2007-10-25
EP2013619A2 (en) 2009-01-14
HUE036378T2 (hu) 2018-07-30
BRPI0710054A2 (pt) 2011-08-02
JP2009533056A (ja) 2009-09-17
SE1050445A1 (sv) 2010-05-04
SE0850071L (sv) 2008-12-19
WO2007120699A3 (en) 2008-01-24
EP2013619B1 (en) 2017-10-11

Similar Documents

Publication Publication Date Title
BRPI0710054B8 (pt) métodos para identificar um ou uma pluralidade de metabólitos celulares, para triar um composto de teste, e, para testar um composto de teste
BRPI0613429A2 (pt) inibidores de histona desacetilase
ES2422735T3 (es) Procedimiento para la predicción de un riesgo de reacciones adversas a medicamentos mediante la determinación de HLA-B 1502
MX2014003153A (es) Prediccion de riesgo de evento cardiovascular y usos del mismo.
CR20110309A (es) Compuestos orgánicos
DE602006017365D1 (de) Zusammensetzungen für die identifizierung von adenoviren
BRPI0915619A2 (pt) métodos para determinar uma probabilidade de que um sujeito tenha contribuído com material genético para amostra de teste de material genético, para caracterizar amostra de teste de material genético e para determinar se uma pessoa de interesse contribuiu com material genético para uma amostra de teste de material genético, kit para análise de amostra de teste de material genético e sistema para determinar se um sujeito contribuiu com material genético para uma amostra
EA201491833A1 (ru) Основанные на клетках перекрестные анализы и их применение
NI200700287A (es) Inhibidores de la fosfolipasa a2 citosolica
UY31806A (es) Compuestos de tiazole y oxazole de sulfonamida de benceno
BRPI0506843A (pt) composto, composição farmacêutica, processo para a preparação de um composto, e, uso de um composto
DE602006015793D1 (de) Proteolipidmembran und lipidmembranen-biosensor
WO2007114986A3 (en) Cooperative probes and methods of using them
MX2007004342A (es) Moleculas cop1 y uso de las mismas.
EP1802766A4 (en) METHOD FOR A GLOBAL COOLING AND FIBRINOLYSIS TEST
BRPI0907656A2 (pt) composto para testar a pureza de cisatracúrio, método para testar a pureza de uma amostra de besilato de cisatracúrio, uso de um composto para testar a pureza de cisatracúrio e processo para preparar compostos para testar a pureza de cisatracúrio
AR060440A1 (es) Agonistas receptores de eritropoietina
ATE541216T1 (de) Fluoreszenztestverfahren
ATE514081T1 (de) T-zellen-testverfahren
BRPI0906090A2 (pt) substrato para análise de uma enzima, molécula e método para detectar atividade enzimática .
DK2005190T3 (da) Inhibering af gasc1
MX2012000041A (es) Metodo para someter a prueba a un sujeto que se cree esta predispuesto a tener cancer metastasico usando delta133p53beta.
ATE531822T1 (de) Diagnose von prostatakrebs
ATE403151T1 (de) Trägerplatte zur durchführung funktioneller tests an biologischen zellen sowie verfahren zur beschichtung der trägerplatte
AR086043A1 (es) Sistema de ensayo y metodos para identificar un compuesto que altera la actividad celular del ddr

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 17/11/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 10/04/2007, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO